Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7224202 | 0.87 | KDM4E (0.48) | ALDH1A1CYP3A4HIF1AMAPTSMN1; SMN2 | |
| SCHEMBL27751566 | 0.85 | NCF1 (0.47) | NCF1CYP1A2ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL826018 | 0.84 | NCF1 (0.50) | NCF1CYP1A2ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL13868217 | 0.81 | NCF1 (0.47) | NCF1CYP1A2ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL1496289 | 0.81 | NCF1 (0.47) | NCF1CYP1A2ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL15576240 | 0.81 | NCF1 (0.47) | NCF1CYP1A2ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL14431011 | 0.81 | NCF1 (0.47) | NCF1CYP1A2ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL9576579 | 0.81 | NCF1 (0.47) | NCF1CYP1A2ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL19272107 | 0.81 | NCF1 (0.47) | NCF1CYP1A2ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL14120837 | 0.81 | NCF1 (0.52) | NCF1CYP1A2ALDH1A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6620823-B2 | Antiinflammatory agents; rheumatic disorders | BRISTOL-MYERS SQUIBB PHARME COMPANY | 2003-09-16 | — | — | US | claimed |
| US-6984648-B2 | Cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-01-10 | — | — | US | disclosed |
| US-6962938-B2 | Spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-08 | — | — | US | disclosed |
| US-6884806-B2 | Bicyclic lactam derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-26 | — | — | US | disclosed |
| US-6743807-B2 | TREATMENT OF RHEUMATOID AND OSTEOARTHRITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, TUMOR METASTASIS OR INVASION, PERIODONTAL DISEASE AND BONE DISEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-6720329-B2 | ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB PHARMA | 2004-04-13 | — | — | US | disclosed |
| US-6642255-B2 | Substituted carbocyclic or heterocyclic hydroxamic acid derivatives, e.g., (3R,4S)-N-hydroxy-1-methyl-3-(((4-((2-methyl-4 -quinolinyl)methoxylphenyl)sulfonyl)methyl)-4-piperidinecarboxamide | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-11-04 | — | — | US | disclosed |
| US-6620823-B2 | Antiinflammatory agents; rheumatic disorders | BRISTOL-MYERS SQUIBB PHARME COMPANY | 2003-09-16 | — | — | US | disclosed |
| US-6610731-B2 | Antiinflammatory | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-26 | — | — | US | disclosed |
| EP-1299379-A2 | LACTAM METALLOPROTEASE INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2003-04-09 | — | — | EP | disclosed |
| EP-1165546-A2 | NOVEL LACTAM INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-ALPHA, AND AGGRECANASE | Du Pont Pharmaceuticals Company (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-1165500-A1 | AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES,TNF-ALPHA,AND AGGRECANASE | Du Pont Pharmaceuticals Company (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001070673-A2 | CYCLIC β-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-$g(a) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
| EP-1054877-A1 | NOVEL CYCLIC SULFONAMIDE DERIVATIVES AS METALLOPROTEINASE INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000059874-A1 | NOVEL AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000059285-A2 | NOVEL LACTAM INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-10-12 | — | — | WO | disclosed |
| EP-1027332-A1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-08-16 | — | — | EP | disclosed |
| US-6057336-A | ANTIINFLAMMATORY AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-05-02 | — | — | US | disclosed |
| WO-1999041246-A1 | NOVEL CYCLIC SULFONAMIDE DERIVATIVES AS METALLOPROTEINASE INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-08-19 | — | — | WO | disclosed |
| WO-1999018074-A1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | Britol-Myers Squibb Pharma Company (US) | 1999-04-15 | — | — | WO | disclosed |